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Background
Atherosclerotic peripheral arterial disease is associated with an increased risk of myo-
cardial infarction, stroke, and death from cardiovascular causes. Antiplatelet drugs 
reduce this risk, but the role of oral anticoagulant agents in the prevention of car-
diovascular complications in patients with peripheral arterial disease is unclear.
Methods
We assigned patients with peripheral arterial disease to combination therapy with 
an antiplatelet agent and an oral anticoagulant agent (target international normal-
ized ratio [INR], 2.0 to 3.0) or to antiplatelet therapy alone. The first coprimary out-
come was myocardial infarction, stroke, or death from cardiovascular causes; the sec-
ond coprimary outcome was myocardial infarction, stroke, severe ischemia of the 
peripheral or coronary arteries leading to urgent intervention, or death from cardio-
vascular causes.
Results
A total of 2161 patients were randomly assigned to therapy. The mean follow-up time 
was 35 months. Myocardial infarction, stroke, or death from cardiovascular causes oc-
curred in 132 of 1080 patients receiving combination therapy (12.2%) and in 144 of 
1081 patients receiving antiplatelet therapy alone (13.3%) (relative risk, 0.92; 95% con-
fidence interval [CI], 0.73 to 1.16; P = 0.48). Myocardial infarction, stroke, severe ische-
mia, or death from cardiovascular causes occurred in 172 patients receiving combina-
tion therapy (15.9%) as compared with 188 patients receiving antiplatelet therapy 
alone (17.4%) (relative risk, 0.91; 95% CI, 0.74 to 1.12; P = 0.37). Life-threatening bleed-
ing occurred in 43 patients receiving combination therapy (4.0%) as compared with 
13 patients receiving antiplatelet therapy alone (1.2%) (relative risk, 3.41; 95% CI, 1.84 
to 6.35; P<0.001).
Conclusions
In patients with peripheral arterial disease, the combination of an oral anticoagulant 
and antiplatelet therapy was not more effective than antiplatelet therapy alone in pre-
venting major cardiovascular complications and was associated with an increase in 
life-threatening bleeding. (ClinicalTrials.gov number, NCT00125671.)
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Peripheral arterial disease is most commonly caused by atherosclerosis and is a sign that widespread atherosclerotic vas-
cular disease is present. Patients with peripheral 
arterial disease have a risk of myocardial infarc-
tion, stroke, or death from cardiovascular causes 
that is three times as high as persons without pe-
ripheral arterial disease.1,2 Antiplatelet therapy re-
duces the incidence of major cardiovascular events 
in patients with peripheral arterial disease.3
Oral anticoagulant agents, with or without an-
tiplatelet therapy, reduce the rate of major cardio-
vascular events in patients with coronary artery 
disease. The American College of Cardiology and 
the American Heart Association consider oral anti-
coagulation in combination with aspirin to be an 
appropriate alternative to aspirin alone in patients 
who have had a myocardial infarction with ST el-
evation.4-7 Information regarding the efficacy and 
safety of oral anticoagulation, with or without an-
tiplatelet therapy, in patients with peripheral arte-
rial disease is limited.8 We therefore conducted a 
randomized trial to determine whether oral anti-
coagulation (target international normalized ratio 
[INR], 2.0 to 3.0) in combination with antiplate-
let therapy is superior to antiplatelet therapy alone 
in patients with peripheral arterial disease.
Me thods
Study design
We conducted this randomized, open-label, clini-
cal trial at 80 centers in Canada, Poland, Hungary, 
Ukraine, China, the Netherlands, and Australia. 
Details of the study design have been published 
previously.8 The study was coordinated by the Pop-
ulation Health Research Institute at McMaster Uni-
versity in Hamilton, Ontario, Canada. The proto-
col was approved by the ethics review boards of all 
participating institutions, and all patients provided 
written informed consent.
The Warfarin Antiplatelet Vascular Evaluation 
(WAVE) trial was sponsored by the Canadian Insti-
tutes of Health Research, the Heart and Stroke 
Foundation of Ontario, and the Population Health 
Research Institute. Donations were also provided 
by Roche Diagnostics (in kind) and DuPont Phar-
ma. In Hungary, acenocoumarol was provided by 
ICN Pharma. None of the corporate sponsors had 
any role in the design or conduct of the trial, 
analysis of the data, or preparation of the manu-
script.
Patient Eligibility
Men and women who were 35 to 85 years of age 
and had peripheral arterial disease were eligible for 
enrollment in the trial. Peripheral arterial disease 
was defined as atherosclerosis of the arteries of the 
lower extremities, the carotid arteries, or the sub-
clavian arteries. Atherosclerosis of the lower ex-
tremities was defined as intermittent claudication 
with objective evidence of peripheral arterial dis-
ease, ischemic pain at rest, nonhealing ulcers or 
focal gangrene, previous amputation, arterial re-
vascularization, or the blue toe syndrome. Carotid 
artery disease was defined as a transient ischemic 
attack or stroke more than 6 months before enroll-
ment, carotid endarterectomy, or asymptomatic 
carotid stenosis of more than 50%. Patients were 
excluded from the study if they had an indication 
for oral anticoagulant treatment, were actively 
bleeding or were at high risk for bleeding, had had 
a stroke within 6 months before enrollment, or re-
quired dialysis.
Randomization and Study Medications
Patients who provided written informed consent 
entered an active run-in phase for 2 to 4 weeks, dur-
ing which they received both oral anticoagulant 
therapy and antiplatelet therapy. Acceptable anti-
platelet agents included aspirin (recommended 
dose, 81 to 325 mg per day), ticlopidine, and clopid-
ogrel. Warfarin was used for oral anticoagulation 
in five countries, and acenocoumarol was used in 
Poland and Hungary.
If a stable INR between 2.0 and 3.0 was achieved 
during the run-in phase, the patient agreed to con-
tinue and adhered to therapy, and no side effects 
had occurred, a central 24-hour computerized ran-
domization service was used to assign the patient 
to either the combination of oral anticoagula-
tion and antiplatelet therapy (1080 patients) or 
antiplatelet therapy alone (1081 patients). A per-
muted-block randomization stratified according 
to clinical center was used. All study participants 
continued taking the antiplatelet agent they were 
receiving at the time of the active run-in. Dual 
antiplatelet therapy was not permitted unless the 
patient had an acute coronary syndrome or place-
ment of a coronary stent during follow-up.
Follow-up and Assessment of End Points
After randomization, INR values were measured 
every month or more frequently, at the discretion 
of the local physician. Patients were followed for 
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a minimum of 2.5 years or a maximum of 3.5 years. 
Follow-up assessments occurred every 3 months, 
when information on events, other hospitaliza-
tions, and adherence to the assigned treatment 
regimen was obtained.
Study Outcomes
Two coprimary composite outcomes were defined. 
Coprimary outcome 1 was myocardial infarction, 
stroke, or death from cardiovascular causes; copri-
mary outcome 2 was myocardial infarction, stroke, 
severe ischemia of the peripheral or coronary ar-
teries leading to urgent intervention, or death from 
cardiovascular causes. The safety outcomes were 
life-threatening, moderate, or minor bleeding epi-
sodes. All outcomes were determined by the mem-
bers of a central adjudication committee who used 
standard definitions and were unaware of treat-
ment allocation. An independent data and safety 
monitoring board monitored the study regularly; 
safety data were assessed every 6 months or more 
frequently, as requested by the data and safety 
monitoring board.
Death from cardiovascular causes was defined 
as any death for which there was no clearly docu-
mented noncardiovascular cause. Myocardial in-
farction was defined as the presence of at least two 
of the following three findings: typical ischemic 
chest pain; elevation of the level of serum creatine 
kinase, serum creatine kinase MB fraction, or se-
rum troponin; and diagnostic electrocardiographic 
changes. Stroke was defined as a new focal neu-
rologic deficit lasting more than 24 hours. Strokes 
were classified as ischemic or hemorrhagic (in-
cluding subarachnoid hemorrhage) if a computed 
tomographic or magnetic resonance imaging scan 
or an autopsy report was available. All other 
strokes were classified as of uncertain cause. Se-
vere coronary ischemia was defined as unstable 
angina with electrocardiographic changes requir-
ing hospitalization and leading to coronary revas-
cularization. Severe peripheral ischemia was de-
fined as ischemia threatening the viability of the 
limb and leading to thrombolytic therapy, angio-
plasty, bypass surgery, or amputation.
Bleeding was categorized as life-threatening, 
moderate, or minor. Life-threatening bleeding was 
defined as fatal or intracranial bleeding or bleed-
ing requiring surgical intervention or transfusion 
of a total of at least 4 units of blood or blood 
products, including fresh-frozen plasma. Moder-
ate bleeding was defined as intraocular hemor-
rhage or as bleeding that the treating physician 
determined required transfusion of 1 to 3 units 
of blood or blood products. All other bleeding was 
classified as minor.
Statistical Analysis
The original trial protocol (see the Supplementary 
Appendix, available with the full text of this article 
at www.nejm.org) estimated that random assign-
ment of 2400 patients equally to the two treatment 
groups with a follow-up of 2.5 years would provide 
more than 80% power to detect an observed risk 
reduction of 25% in coprimary outcome 1 (estimat-
ed event rate in the control group, 13.8%) and 
more than 90% power to detect risk reduction of 
25% in coprimary outcome 2 (estimated event rate 
in the control group, 24.1%). Both calculations 
assumed a 15% rate of nonadherence to oral anti-
coagulation and a 5% rate of use of oral antico-
agulation in the control group.
The original power calculation estimated that 
2400 patients would be required, but recruitment 
of patients was slower than expected. Therefore, 
on September 27, 2002, in order to maintain study 
power, the steering committee stopped recruit-
ment at 2161 patients and recommended extend-
ing the follow-up period from 2.5 years to 3.5 years 
for the 1396 patients already enrolled in the study.
The primary analysis compared treatment 
groups with respect to the first occurrence of an 
event in each of the two coprimary outcomes us-
ing a log-rank statistic based on an intention-to-
treat analysis. Assessment of the treatment effect 
of adherence to oral anticoagulation was per-
formed by comparing results from centers with 
good adherence (at least 70% of patients using oral 
anticoagulation over the course of follow-up) to 
results from centers with poor adherence (less 
than 70% of patients using oral anticoagulation 
over the course of follow-up).9 Among patients re-
ceiving oral anticoagulation, the time in the thera-
peutic range was calculated by the linear-interpo-
lation method described by Rosendaal et al.10 All 
reported P values are two-sided and are not ad-
justed for multiple testing.
R esult s
Baseline Characteristics
Between April 2000 and September 2003, a total 
of 2417 eligible, consenting patients were entered 
into the run-in phase of the trial (see the Supple-
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mentary Appendix). Of these, 2161 entered the 
randomized phase. The most common reasons 
for not continuing into the randomized phase 
were patient refusal (115 patients), poor adherence 
to oral anticoagulant therapy (50 patients), inabil-
ity to maintain a stable INR (43 patients), and 
bleeding (23 patients).
The baseline characteristics of the patients par-
ticipating in the randomized phase of the trial are 
shown in Table 1. The mean age was 64 years, and 
73.6% were men. Most of the patients (81.8%) had 
peripheral arterial disease of the lower extremities. 
At baseline, 98.4% of the patients were receiving 
some form of antiplatelet therapy.
Follow-up and adherence to treatment
The mean duration of follow-up was 35 months 
(1043 days). A total of 1073 patients (49.7%) were 
followed for 2.5 years, and 1088 patients (50.3%) 
were followed for 3.5 years. Two patients (both in 
the combination-therapy group) withdrew consent 
and could not be contacted. Therefore, complete 
data at the end of the study were available for 
2159 of the patients randomly assigned to treat-
ment (99.9%); data on the 2 who withdrew that 
were obtained up to the time of last contact were 
also included. In the combination-therapy group, 
oral anticoagulation was permanently discontin-
ued in 319 patients (29.5%) and antiplatelet thera-
py was permanently discontinued in 53 (4.9%); in 
the group receiving only antiplatelet therapy, an-
tiplatelet agents were permanently discontinued in 
21 patients (1.9%) and 45 patients (4.2%) began 
using nonstudy oral anticoagulants (see the Sup-
plementary Appendix). Among patients receiv-
ing oral anticoagulation, the mean INR was 2.2; 
62.0% of the time, INR values were in the thera-
peutic range (2.0 to 3.0); 30.8% of the time, they 
were below 2.0; and 7.2% of the time, they were 
above 3.0.10
During follow-up, the use of statins, angioten-
sin-converting–enzyme inhibitors, and beta-block-
ers increased moderately while the use of pentox-
ifylline decreased. Peripheral revascularization was 
performed in 76 patients (3.5%), limb amputation 
in 20 (0.9%), and coronary-artery bypass grafting 
in 25 (1.2%). There were no significant differ-
ences in the use of these medications or proce-
dures between the two study groups (see the Sup-
plementary Appendix).
Outcomes
The first coprimary composite end point (myocar-
dial infarction, stroke, or death from cardiovascu-
lar causes) occurred in 132 of the 1080 patients in 
the combination-therapy group (12.2%), as com-
pared with 144 of the 1081 patients in the anti-
platelet-therapy group (13.3%) (relative risk, 0.92; 
95% confidence interval [CI], 0.73 to 1.16; P = 0.48). 
The second coprimary composite end point (myo-
cardial infarction, stroke, severe ischemia of the 
coronary or peripheral arteries, or death from car-
diovascular causes) occurred in 172 patients in the 
combination-therapy group (15.9%) and 188 pa-
tients in the antiplatelet-therapy group (17.4%) (rel-
ative risk, 0.91; 95% CI, 0.74 to 1.12; P = 0.37). 
Figure 1 shows the cumulative risks of the two 
coprimary outcomes for each treatment group. As 
shown in Table 2, no significant differences were 
observed between treatment groups with respect 
to the primary outcome components of death from 
cardiovascular causes (6.1% vs. 6.0%; relative risk, 
1.04), myocardial infarction (5.0% vs. 6.1%; relative 
risk, 0.82), stroke (3.5% vs. 3.5%; relative risk, 1.01), 
and severe ischemia (5.7% vs. 5.5%; relative risk, 
1.06).
Adverse Events
Both life-threatening bleeding (4.0% vs. 1.2%; rel-
ative risk, 3.41; 95% CI, 1.84 to 6.35; P<0.001) 
and moderate bleeding (2.9% vs. 1.0%; relative 
risk, 2.82; 95% CI, 1.43 to 5.58; P = 0.002) were 
increased in the combination-therapy group as 
compared with the antiplatelet-therapy group (Ta-
ble 2). Figure 2 shows the cumulative risk of life-
threatening bleeding in the two groups. There 
were 14 hemorrhagic strokes (1.3%) in the com-
bination-therapy group and none in the anti-
platelet-therapy group (relative risk, 15.2; 95% CI, 
2.0 to 115.6; P = 0.001). Minor bleeding was also 
significantly increased (38.6% vs. 10.6%; relative 
risk, 3.63; 95% CI, 3.01 to 4.38; P<0.001) After 
removal of fatal bleeding and hemorrhagic stroke 
from coprimary outcome 1, the risk of coprimary 
outcome 1 was 10.8% in the combination-therapy 
group as compared with 13.2% in the antiplatelet-
therapy group (relative risk, 0.82; 95% CI, 0.64 to 
1.05). The relative risk of coprimary outcome 2 af-
ter removal of fatal bleeding and hemorrhagic 
stroke from the outcome was similar (relative risk, 
0.83; 95% CI, 0.67 to 1.03) (Table 2).
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Prespecified and Exploratory Subgroup 
Analyses
The treatment effect on both efficacy outcomes, as 
well as on the incidence of bleeding, was statisti-
cally consistent in all subgroup analyses (Fig. 3). 
No differential effect on the first coprimary out-
come was detected when centers were categorized 
according to their level of adherence. The relative 
risk of death from cardiovascular causes, myocar-
dial infarction, or stroke was 0.98 (95% CI, 0.49 to 
1.97) for centers with adherence of 70% or greater 
and 0.91 (95% CI, 0.71 to 1.17) for centers with 
Table 1. Baseline Characteristics of the Patients.*
Characteristic
Oral Anticoagulant  
plus Antiplatelet Therapy 
(N = 1080)
Antiplatelet 
Therapy Alone 
(N = 1081) P Value
Age — yr 63.9±9.4 63.8±9.5 0.88
Male sex — no. (%) 796 (73.7) 795 (73.5) 0.93
Hypertension — no. (%) 630 (58.3) 628 (58.1) 0.84
Diabetes — no. (%) 290 (26.9) 298 (27.6) 0.71
Smoking history — no. (%)
Current smoker 318 (29.4) 315 (29.1) 0.88
Former smoker 518 (48.0) 533 (49.3) 0.53
Coronary artery disease — no. (%)† 483 (44.7) 539 (49.9) 0.02
Stroke — no. (%) 166 (15.4) 177 (16.4) 0.52
Qualifying condition — no. (%) 
Peripheral arterial disease of the lower  
extremities
880 (81.5) 887 (82.1) 0.73
Other peripheral arterial disease‡ 200 (18.5) 194 (17.9) 0.73
Blood pressure — mm Hg 
Systolic 137.0±18.7 137.0±18.6 0.92
Diastolic 78.1±10.5 78.0±10.6 0.89
Ankle–brachial index§ 0.82
Median 0.83 0.84
Interquartile range 0.7–1.0 0.7–1.0
Medications — no. (%)
Antiplatelet agents 1062 (98.3) 1065 (98.5) 0.73
Aspirin 999 (92.5) 986 (91.2) 0.27
Ticlopidine 30 (2.8) 44 (4.1) 0.09
Clopidogrel 35 (3.2) 40 (3.7) 0.56
Hydroxymethylglutaryl–coenzyme A reductase  
inhibitors (statins)
462 (42.8) 489 (45.2) 0.25
Any lipid-lowering medication 588 (54.4) 603 (55.8) 0.53
Angiotensin-converting–enzyme inhibitors 545 (50.5) 544 (50.3) 0.95
Beta-blockers 343 (31.8) 347 (32.1) 0.86
* Plus–minus values are means ±SD.
† Coronary artery disease is defined as a history of myocardial infarction, angina, percutaneous coronary intervention, or 
coronary-artery bypass surgery.
‡ Other peripheral arterial disease is defined as subclavian arterial stenosis, prior carotid endarterectomy, transient ische-
mic attack or stroke more than 6 months before enrollment, or asymptomatic carotid stenosis of more than 50%.
§ Measurements of the ankle–brachial index were available for 771 patients receiving combination therapy and 759 pa-
tients receiving antiplatelet therapy alone.
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adherence of less than 70%.9 In an exploratory 
subgroup analysis, the treatment effect among all 
participating countries was compared, and hetero-
geneity of borderline statistical significance was 
observed (chi-square = 12.20, P = 0.06). The relative 
risk of the first coprimary outcome appeared to be 
increased among patients in China (relative risk, 
2.62; 95% CI, 1.25 to 5.47), whereas it was lower in 
other countries (see the Supplementary Appendix).
Discussion
In the WAVE trial, we compared the efficacy and 
safety of combination antithrombotic therapy with 
an antiplatelet agent and an oral anticoagulant (tar-
get INR, 2.0 to 3.0) with the efficacy and safety of 
antiplatelet therapy alone in patients with periph-
eral arterial disease. We found that combination 
therapy was not more effective than antiplatelet 
therapy alone in preventing major cardiovascular 
complications. Instead, combination therapy was 
associated with a substantial excess of life-threat-
ening bleeding as well as other bleeding.
Antiplatelet agents reduce the incidence of ma-
jor cardiovascular events in patients with periph-
eral arterial disease,3,11 and therefore it was rea-
sonable to consider the possibility that the addition 
of an anticoagulant (such as warfarin) to an anti-
platelet agent would increase this benefit. This 
hypothesis was further supported by the favorable 
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Figure 1. Cumulative Incidence of the Coprimary End Points in the Two Treatment Groups.
Panel A shows the cumulative incidence of the first coprimary end point (myocardial infarction, stroke, or death 
from cardiovascular causes). There was no significant difference in outcome between the group receiving combina-
tion therapy with an oral anticoagulant and an antiplatelet agent and the group receiving an antiplatelet agent alone 
(relative risk, 0.92; 95% CI, 0.73 to 1.16; P = 0.48). Panel B shows the cumulative incidence of the second coprimary 
end point (myocardial infarction, str ke, severe ischemia of the peripheral or coronary arteries leading to urgent in-
tervention, or death from cardiovascular causes). There was no significant difference in outcome between the two 
groups (relative risk, 0.91; 95% CI, 0.74 to 1.12; P = 0.37). 
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effects of the combination of moderate-intensity 
oral anticoagulant therapy and antiplatelet therapy 
in patients with coronary artery disease.5-7,12 Few 
randomized trials had tested this hypothesis be-
fore our study, and clinical practice was therefore 
variable.8,13
In the WAVE trial, we aimed to maximize ad-
herence to oral anticoagulant therapy and to mini-
mize bleeding. We therefore excluded patients 
with known risk factors for bleeding, such as long-
term use of nonsteroidal antiinflammatory drugs, 
previous gastrointestinal bleeding, or recent stroke. 
In addition, the active run-in excluded patients 
with unstable INR values, minor bleeding, or poor 
adherence to oral anticoagulant therapy. Despite 
these efforts, 29.5% of patients discontinued oral 
anticoagulant therapy during follow-up. This rate 
is consistent with the adherence levels achieved in 
other large clinical trials of long-term oral anti-
coagulation.4,14 The INR values of participants 
assigned to oral anticoagulation were in the thera-
peutic range (2.0 to 3.0) 62% of the time, demon-
strating a level of anticoagulant control similar to 
that achieved in most trials.
On the basis of previous clinical trials,14 we 
expected that the rates of minor, and possibly of 
moderate, bleeding would be significantly in-
creased in the combination-therapy group. How-
ever, we also expected that the benefits of treat-
ment would outweigh the risks. Although the 
P value was nonsignificant, the lower border of 
the 95% confidence interval does not totally ex-
Table 2. Primary and Secondary Outcomes.*
Outcome
Oral Anticoagulant 
plus Antiplatelet 
Therapy  
(N =1080)
Antiplatelet  
Therapy Alone  
(N = 1081)
Combination Therapy  
vs. Antiplatelet Therapy Alone
Relative Risk  
(95% CI) P Value
no. (%)
Coprimary outcome 1† 132 (12.2) 144 (13.3) 0.92 (0.73–1.16) 0.48
Coprimary outcome 2‡ 172 (15.9) 188 (17.4) 0.91 (0.74–1.12) 0.37
Death from any cause 99 (9.2) 96 (8.9) 1.04 (0.79–1.38) 0.76
Death from cardiovascular causes 66 (6.1) 65 (6.0) 1.04 (0.74–1.46) 0.84
Myocardial infarction 54 (5.0) 66 (6.1) 0.82 (0.57–1.18) 0.28
Stroke 38 (3.5) 38 (3.5) 1.01 (0.65–1.59) 0.96
Ischemic or of uncertain cause 24 (2.2) 38 (3.5) 0.64 (0.38–1.06) 0.09
Hemorrhagic 14 (1.3) 0 15.2 (2.0–115.6) 0.001
Severe ischemia 62 (5.7) 59 (5.5) 1.06 (0.74–1.51) 0.76
Coronary 20 (1.9) 15 (1.4) 1.35 (0.69–2.64) 0.38
Lower extremities 42 (3.9) 44 (4.1) 0.96 (0.63–1.47) 0.86
Fatal bleeding 10 (0.9) 3 (0.3) 3.34 (0.92–12.1) 0.05
Life-threatening bleeding 43 (4.0) 13 (1.2) 3.41 (1.84–6.35) <0.001
Intracranial bleeding 14 (1.3) 0 15.2 (2.0–115.6) 0.001
Moderate bleeding 31 (2.9) 11 (1.0) 2.82 (1.43–5.58) 0.002
Life-threatening or moderate bleeding 74 (6.9) 24 (2.2) 3.21 (2.02–5.08) <0.001
Minor bleeding 417 (38.6) 115 (10.6) 3.63 (3.01–4.38) <0.001
Coprimary outcome 1 with no fatal bleeding 
or hemorrhagic stroke 
117 (10.8) 143 (13.2) 0.82 (0.64–1.05) 0.11
Coprimary outcome 2 with no fatal bleeding 
or hemorrhagic stroke 
157 (14.5) 187 (17.3) 0.83 (0.67–1.03) 0.09
* CI denotes confidence interval.
† Coprimary outcome 1 was myocardial infarction, stroke, or death from cardiovascular causes.
‡ Coprimary outcome 2 was myocardial infarction, stroke, severe ischemia of the peripheral or coronary arteries, or death 
from cardiovascular causes.
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clude a 25% relative risk reduction. Our results are 
consistent with those of the Department of Vet-
erans Affairs Cooperative Study, the only other 
large, randomized trial comparing a combination 
of oral anticoagulant and antiplatelet therapy with 
antiplatelet therapy alone in patients with periph-
eral arterial disease.13 Both trials showed no sig-
nificant reduction in myocardial infarction, stroke, 
or death from cardiovascular causes, and both 
showed a significant increase in life-threatening 
and moderate bleeding.
We observed a significant increase in life-
threatening bleeding complications, including fa-
tal bleeding and hemorrhagic stroke, with com-
bination therapy as compared with antiplatelet 
therapy alone, despite the fact that very few pa-
tients had an INR above 3.0. Excluding fatal bleed-
ing and hemorrhagic stroke from the coprimary 
outcomes results in risk reductions that are more 
favorable with combination therapy than with an-
tiplatelet therapy alone and suggests that the ex-
cess bleeding that occurred in patients receiving 
combination therapy “neutralized” any benefit of 
that therapy. 
The rates of serious bleeding and hemorrhagic 
stroke among patients receiving a combination of 
oral anticoagulant and antiplatelet therapy were 
higher in the WAVE trial (5.5 of 100 and 0.51 of 
100 patient-years, respectively) than in a trial in-
volving patients with coronary artery disease (0.56 
of 100 and 0.12 of 100 patient-years, respectively).6 
However, the WAVE results are similar to those of 
another large trial involving patients with periph-
eral arterial disease that compared oral anticoagu-
lation (target INR, 3.0 to 4.5) with aspirin; in that 
trial the rates of serious bleeding and hemor-
rhagic stroke among patients receiving oral anti-
coagulant therapy were 4.1 of 100 and 0.61 of 100 
patient-years, respectively.15 Therefore, it appears 
that patients with peripheral arterial disease who 
are treated with oral anticoagulation may be more 
likely to have bleeding complications, including 
hemorrhagic stroke, than are patients with coro-
nary artery disease. The reason for this difference 
may be that patients with peripheral arterial dis-
ease are older and have more systemic atheroscle-
rosis, including cerebrovascular disease, and more 
coexisting conditions.16
Secondary analyses revealed that the efficacy 
and safety of combination therapy did not differ 
among several patient subgroups of clinical im-
portance. In an exploratory subgroup analysis ac-
cording to country, some heterogeneity of the 
treatment effect was observed. The relative risk of 
the first coprimary outcome (myocardial infarc-
tion, stroke, or death from cardiovascular causes) 
was increased among patients from China. Since 
this qualitative interaction was unexpected, the 
most likely explanation for this finding is chance. 
However, it has been suggested that the optimal 
target INR may be lower for Chinese patients than 
for whites,17 and the possibility of a differential 
response to combination therapy among Chinese 
patients therefore cannot be ruled out.
One potential limitation of the trial was the 
open-label design, which permitted patients and 
their physicians to know which study regimen they 
were receiving. This knowledge could have influ-
enced clinical decisions regarding other medical 
therapy or procedures. However, no significant dif-
ferences between the two study groups in interim 
management were identified (see the Supplemen-
tary Appendix). Furthermore, all trial end points 
were centrally adjudicated by a blinded adjudica-
tion committee.
On the basis of the WAVE results, oral antico-
agulation combined with antiplatelet therapy is not 
indicated in patients with peripheral arterial dis-
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ease, since no significant benefit was observed and 
substantial risk was incurred. According to our 
data, treating 1000 patients with combination 
therapy as compared with antiplatelet therapy 
alone for 3 years would lead to 24 fewer cardio-
vascular events but 28 more episodes of life-threat-
ening bleeding, resulting in a net increase in seri-
ous adverse outcomes. Our findings highlight the 
need to evaluate alternatives to vitamin K antago-
nists in patients with peripheral arterial disease.18
In conclusion, we compared the efficacy and 
safety of antiplatelet therapy combined with oral 
anticoagulation (target INR, 2.0 to 3.0) with the 
efficacy and safety of antiplatelet therapy alone in 
patients with peripheral arterial disease. We found 
that combination therapy was not more effective 
than antiplatelet therapy alone in preventing ma-
jor cardiovascular complications and was associ-
ated with a substantial increase in the risk of life-
threatening bleeding.
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Appendix
The following investigators participated in the WAVE trial: Steering Committee: principal investigator, S. Anand; chair of steering com-
mittee, S. Yusuf; study coordinators, P. Montague, S.L. Chin; regional representatives, A. Budaj, C. Cina, H. Lee (deceased), S. Sauve, 
R. Guzman, G. Hajjar, G. Gosselin, D. Gossard, B. Sussex, R. Crowell, J. Eikelboom, M. Keltai, A. Parkhomenko, L.S. Liu, H. van Urk; 
Investigators (with the number of patients shown in parentheses): Australia — J. Eikelboom (16) (national coordinator); Canada — Al-
berta, R. Moore (12); British Columbia, W. Leong (6), R. Smith (30), K. Woo, J. Imrie (2); Manitoba, R. Guzman (125); Newfoundland, B. 
Sussex (78); Nova Scotia, R. Crowell (101); Ontario, S. Anand (national coordinator), R. Bhargava (6), Y.K. Chan (19), C. Cina (102), S. 
Fratesi (103), B. Geerts (7), G. Hajjar (27), G. Kuruvilla (18), C. Lai (17), H. Lee (103), S. Nawaz (11), S. Sauve (37); Quebec, P. Bolduc 
(22), D. Gossard (27), G. Gosselin (49), R. Labbé (37), P. Nault (5), D. Pilon (12), G. Pruneau (14), D. Savard (2), R. St.-Hilaire (11); 
China — L.S. Liu, S.C. Xu, Y.L. Li (national coordinator), L.L. Deng (23), L. Fan (7), X.H. Fang (21), P. Feng (7), B.X. Guo (7), B.L. Hu 
(8), X.J. Jiang (9), J.H. Liu (2), L.H. Liu (12), X.Q. Liu (6), F.H. Lu (34), X.Y. Shi (8), R.S. Wang (13), Y.X. Wang (114), Q. Yuan, S.B. 
Wu (38), L. Zhang (23), X.M. Zhang (13), F. Zhao (2); Hungary — B. Herczeg (5), M. Jozan-Jilling (16), M. Keltai (national coordinator), 
E. Mesko (13), S. Olvaszto (16), G. Sipos (1), P. Soltesz (25), F. Szaboki (8), S. Timar (1); the Netherlands — H. van Urk (national coor-
dinator), O. Schouten (17); Poland — Z. Binio (3), A. Budaj, B. Klosiewicz-Wasek (73) (national coordinator), J. Gorny (11), K. Janik 
(46), T. Kawka-Urbanek (27), J. Maciejewicz (22), P. Miekus (67), F. Monies (85), M. Ogorek (31), J. Surwilo (12), M. Szpajer (96), T. 
Waszyrowski (35), J. Wojciechowski (16), B. Zalska (36), M. Zebrowski (5); Ukraine — Y. Dykun (8), E. Grishina (2), A. Karpenko (49), 
L. Kononenko (148), O. Koval (8), V. Kovalenko (3), V. Netyazhenko (1), A. Parkhomenko (national coordinator), M. Perepelytsa (20), 
T. Pertseva (1), Y. Sirenko (4), A. Skarzhevsky (5); Adjudication: B. Sussex, S. Sauve, cochairs; C. Cina, R. Guzman, B. Klosjewicz-
Wasek; adjudication officers: F. Merali, P. Magloire; adjudication coordinator: L. Joldersma; Operations Committee: S. Anand, S. Yusuf, B. 
Sussex, J. Eikelboom, P. Montague, A. Budaj, H. Lee (deceased), G. Gosselin, M. Keltai; Data and Safety Monitoring Committee: G. 
Dagenais (chair), J.S. Ginsberg, A. Hill, W. Taylor; Project Office: S. Anand, S. Yusuf, P. Montague, S.L. Chin, L. Joldersma, S. Parkin-
son, K. Antaya, D. Sloane, B. Nowacki, P. Magloire, F. Merali; Laboratory: M. McQueen, K. Hall; Biostatistics: C. Xie, J. Pogue, S. 
Hawken; Pharmacy Contact: M. Biljan; Administration: B. Cracknell, K. Antaya.
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